Cumulus Neuroscience

BrainWaveBank is a UK-based startup founded in 2015, with a mission to revolutionize the early diagnosis and treatment response of central nervous system (CNS) disorders. The company's slogan "BrainWaveBank aims to improve early diagnosis and treatment response of CNS disorders through home-based, affordable cognitive health assessments" reflects their commitment to democratizing cognitive health assessments. By offering affordable and accurate cognitive health assessments at people's homes, BrainWaveBank is addressing the critical need for early detection and personalized treatment measurement of CNS disorders at an individual level. The company's innovative approach leverages a neuroinformatics platform powered by AI technology, which enables the creation of precise CNS disorder diagnostics and digital biomarkers, as well as customized therapies. This not only enhances the early detection of CNS disorders but also supports tailored treatment responses. With CNS disorders representing a substantial healthcare burden, exceeding $3 trillion in annual costs, BrainWaveBank's disruptive approach holds the potential to significantly reduce the economic burden on patients and healthcare systems. In December 2020, BrainWaveBank secured a significant £6.00M investment in the form of a Convertible Note investment, with participation from notable investors including Future Fund and LifeArc. This investment is a testament to the confidence of reputable institutions in the potential impact of BrainWaveBank's innovative solutions in the field of cognitive health assessments. With its strategic focus on revolutionizing CNS disorder diagnostics and treatment response, BrainWaveBank is well-positioned to contribute to the advancement of healthcare and create substantial value in the Health Care and Pharmaceutical industries.